Search results for "Platelet"

showing 10 items of 786 documents

Impact of periodontal treatment on the RANKL/OPG ratio in crevicular fluid.

2020

Aim Alveolar resorption is one of the most important events in periodontitis. Osteoclast activity is regulated by the ratio between receptor activator of NF-κB ligand (RANKL) and osteoprotegerin (OPG). The aim of this study was to evaluate changes in the RANKL/OPG ratio in crevicular fluid after periodontal treatment. Material and methods A total of 15 patients with periodontitis were included in the study group. Samples were collected from an area with active periodontitis and a healthy area. The RANKL and OPG levels were measured before and after periodontal scaling and root planing (SRP) treatment. The study group was compared to the control group, which included 10 patients without peri…

MaleTeethAlveolar Bone LossOsteoclastsPathology and Laboratory MedicineAntiplatelet TherapyVascular Medicine0302 clinical medicineScaling and root planingOral DiseasesAnimal CellsMedicine and Health SciencesProspective StudiesProspective cohort studyConnective Tissue CellsMultidisciplinarybiologyPharmaceuticsQRGingival Crevicular FluidMiddle AgedHealthy VolunteersTreatment Outcomemedicine.anatomical_structureConnective TissueRANKL030220 oncology & carcinogenesisMedicineFemaleAnatomyCellular TypesPeriodontal IndexResearch Articlemusculoskeletal diseasesmedicine.medical_specialtyScienceOral MedicineHemorrhage03 medical and health sciencesSigns and SymptomsDrug TherapyOsteoprotegerinDiagnostic MedicineOsteoclastInternal medicinemedicineHumansPeriodontitisBonePeriodontal DiseasesAgedPeriodontitisbusiness.industryRANK LigandOsteoprotegerinCase-control studyBiology and Life SciencesRANK LigandCell Biology030206 dentistrymedicine.diseaseBiological TissueEndocrinologyJawCase-Control StudiesChronic Periodontitisbiology.proteinDental ScalingbusinessDigestive SystemHeadPLoS ONE
researchProduct

Staphylococcal α-toxin provokes coronary vasoconstriction and loss in myocardial contractility in perfused rat hearts: Role of thromboxane generation

2000

Background —Cardiac performance is severely depressed in septic shock. Endotoxin has been implicated as the causative agent in Gram-negative sepsis, but similar abnormalities are encountered in Gram-positive sepsis. We investigated the influence of the major exotoxin of Staphylococcus aureus, staphylococcal α-toxin, in isolated perfused rat hearts. Methods and Results —α-Toxin 0.25 to 1 μg/mL caused a dose-dependent increase in coronary perfusion pressure that more than doubled. In parallel, we noted a decrease in left ventricular developed pressure and the maximum rate of left ventricular pressure rise (dP/dt max ), dropping to a minimum of <60% of control. These changes were accompani…

MaleThromboxaneIndomethacinProstacyclinVentricular Function LeftHemolysin ProteinsThromboxane A2chemistry.chemical_compoundEdemaPhenylacetatesSulfonamidesHeartAzepinesPerfusionAnesthesiaLactatesVentricular pressuremedicine.symptomCardiology and Cardiovascular Medicinemedicine.drugStaphylococcus aureusmedicine.medical_specialtyBacterial ToxinsExotoxinsIn Vitro TechniquesSepsisContractilityThromboxane A2Physiology (medical)Internal medicinemedicineAnimalsMasoprocolPlatelet Activating FactorRats WistarAspirinL-Lactate Dehydrogenasebusiness.industryTriazolesmedicine.diseaseEpoprostenolMyocardial ContractionRatsEndocrinologychemistryVasoconstrictionPotassiumCoronary perfusion pressurebusinessPlatelet Aggregation InhibitorsVasoconstriction
researchProduct

A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian …

2022

Background: Oral activated factor XI (FXIa) inhibitors may modulate coagulation to prevent thromboembolic events without substantially increasing bleeding. We explored the pharmacodynamics, safety, and efficacy of the oral FXIa inhibitor asundexian for secondary prevention after acute myocardial infarction (MI). Methods: We randomized 1601 patients with recent acute MI to oral asundexian 10, 20, or 50 mg or placebo once daily for 6 to 12 months in a double-blind, placebo-controlled, phase 2, dose-ranging trial. Patients were randomized within 5 days of their qualifying MI and received dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor. The effect of asundexian on FXIa inhibition…

MaleTicagrelorAspirinMyocardial InfarctionAnticoagulantsHemorrhageFactor XIaPercutaneous Coronary InterventionTreatment OutcomeDouble-Blind MethodPhysiology (medical)HumansFemale03.02. Klinikai orvostanAcute Coronary SyndromeCardiology and Cardiovascular MedicinePrasugrel HydrochloridePlatelet Aggregation InhibitorsAgedCirculation
researchProduct

Do randomized clinical trial selection criteria reflect levels of risk as observed in a general population of acute myocardial infarction survivors? …

2016

IF 4.638; International audience; Background: Few clinical trials have focused on populations with a history of distant myocardial infarction (MI). The PEGASUS trial assessed the impact of dual antiplatelet therapy in such patients, selected by enrichment criteria of high cardiovascular risk. Whether the PEGASUS population reflects the risk of a broader post-MI population is questionable. We analyzed whether 4-year mortality of a routine-practice population would differ according to the inclusion and exclusion criteria used in PEGASUS.Methods: FAST-MI is a nationwide French registry recruiting acute MI patients in November 2005; 2490 patients alive and without recurrent MI at one year were …

MaleTicagrelorMyocardial Infarction030204 cardiovascular system & hematologyCoronary artery diseaselaw.inventionCoronary artery disease0302 clinical medicineRandomized controlled trialRisk FactorslawSecondary PreventionRegistriesSurvivors030212 general & internal medicineMyocardial infarctionRandomized Controlled Trials as TopicAged 80 and overeducation.field_of_studyReperfusion therapyEvidence-Based PharmacotherapyMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemST-elevation myocardial infarctionPopulation SurveillanceInclusion and exclusion criteriaFemaleFranceAtherothrombotic EventsCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtyPopulationAcute St-ElevationAcute myocardial infarctionVorapaxar03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicinemedicineHumansMortalityeducationSelection (genetic algorithm)AgedAspirinbusiness.industryPatient SelectionAntiplatelet therapymedicine.diseaseComorbidityClinical trialAdherencePhysical therapyTherapybusinessFollow-Up Studies
researchProduct

Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute co…

2020

Abstract Aims In a randomized, parallel, blinded study, we investigate the impact of clopidogrel, prasugrel, or ticagrelor on peripheral endothelial function in patients undergoing stenting for an acute coronary syndrome. Methods and results The primary endpoint of the study was the change in endothelium-dependent flow-mediated dilation (FMD) following stenting. A total of 90 patients (age 62 ± 9 years, 81 males, 22 diabetics, 49 non-ST elevation myocardial infarctions) were enrolled. There were no significant differences among groups in any clinical parameter. Acutely before stenting, all three drugs improved FMD without differences between groups (P = 0.73). Stenting blunted FMD in the cl…

MaleTicagrelormedicine.medical_specialtyAcute coronary syndromeAdenosinePrasugrelmedicine.medical_treatment030204 cardiovascular system & hematology03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineInternal medicineClinical endpointHumansMedicineEndotheliumcardiovascular diseases030212 general & internal medicineAcute Coronary SyndromeAgedbusiness.industryStentMiddle Agedmedicine.diseaseClopidogrelCoronary VesselsThrombosisConfidence intervalClopidogrelTreatment OutcomePurinergic P2Y Receptor AntagonistsCardiologyFemaleCardiology and Cardiovascular MedicinebusinessPrasugrel HydrochlorideTicagrelorPlatelet Aggregation Inhibitorsmedicine.drugEuropean Heart Journal
researchProduct

Can new generation P2Y12 inhibitors play a role in microvascular obstruction in STEMI?

2016

MaleTicagrelormedicine.medical_specialtyAdenosinePrasugrel030204 cardiovascular system & hematologySTEMI03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineP2Y12Internal medicinemedicineHumans030212 general & internal medicineAgedbusiness.industryMiddle AgedMagnetic Resonance ImagingMicrovesselsPurinergic P2Y Receptor AntagonistsCardiologyST Elevation Myocardial InfarctionMVOFemaleCardiology and Cardiovascular MedicinebusinessPrasugrelPrasugrel HydrochlorideTicagrelorPlatelet Aggregation InhibitorsMRImedicine.drugInternational Journal of Cardiology
researchProduct

Incremental predictive value of mean platelet volume/platelet count ratio in in-hospital stroke after acute myocardial infarction.

2017

IF 2.558; International audience; Stroke is a serious complication after acute myocardial infarction (AMI) and is associated with an increased risk of death. Though the pathophysiological mechanisms are not exactly known, increased inflammation and platelet reactivity could play an important role in the occurrence of stroke during AMI. We aimed to investigate the relationship between both mean platelet volume (MPV), a parameter of platelet function, and C-reactive protein (CRP) and the occurrence of in-hospital ischemic stroke (IHS) after AMI. Data were obtained from a French regional survey for AMI that included 5976 patients admitted to an intensive care unit (ICU) between 2001 and 2010. …

MaleTime FactorsMESH : StrokeMyocardial InfarctionMESH : AgedMESH: ComorbidityComorbidityMESH: Hospitalization030204 cardiovascular system & hematologyMESH : Platelet Countlaw.inventionMESH: Proportional Hazards Models0302 clinical medicineMESH: Aged 80 and overRisk FactorslawMESH: Risk FactorsOdds Ratio[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/HematologyMESH : FemaleMyocardial infarctionMESH : BiomarkersStrokeMESH: Blood PlateletsAged 80 and overMESH: AgedEjection fractionMESH: Middle AgedMESH : PrognosisbiologyMESH : Mean Platelet Volume[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematologyGeneral MedicineMiddle AgedPrognosisIntensive care unitstrokeMESH : Risk Factors3. Good healthHospitalizationMESH: Myocardial Infarctionrisk factorplateletsMESH : ComorbidityCardiologyMESH : HospitalizationFemaleMean Platelet VolumeMESH : Time FactorsBlood Plateletsmedicine.medical_specialtyMESH : Male[SDV.BC]Life Sciences [q-bio]/Cellular BiologyAcute myocardial infarctionMESH: PrognosisMESH: StrokeC-reactive protein03 medical and health sciencesInternal medicinemedicineHumansMESH : Middle AgedMESH: Platelet Countcardiovascular diseasesRisk factorMean platelet volumeMESH : Aged 80 and overSurvival analysisAgedProportional Hazards ModelsMESH: HumansPlatelet Countbusiness.industry[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyC-reactive proteinMESH: Time FactorsMESH : HumansMESH : Blood Plateletsmedicine.diseaseMESH : Proportional Hazards ModelsMESH: Odds RatioMESH: MaleMESH: Mean Platelet Volumebiology.proteinMESH: BiomarkersMESH : Odds RatioMESH : Myocardial InfarctionbusinessMESH: FemaleBiomarkers030217 neurology & neurosurgery
researchProduct

Sudden sensorineural hearing loss: is there a relationship between routine haematological parameters and audiogram shapes?

2016

Objective: To investigate the relationship between haematological routine parameters and audiogram shapes in patients affected by sudden sensorineural hearing loss (SSNHL). Design: A retrospective study. All patients were divided into four groups according to the audiometric curve and mean values of haematological parameters (haemoglobin, white blood cell, neutrophils and lymphocytes relative count, platelet count, haematocrit, prothrombin time, activated partial thromboplastin time, fibrinogen and neutrophil-to-lymphocite ratio) of each group were statistically compared. The prognostic role of blood profile and coagulation test was also examined. Study sample: A cohort of 183 SSNHL patient…

MaleTime FactorsNeutrophilshaematological parameterAudiologyLanguage and LinguisticsHemoglobinsLeukocyte Count0302 clinical medicineHearingLymphocytes030223 otorhinolaryngologyHematologic Testsmedicine.diagnostic_testComplete blood countAudiogramSudden sensorineural hearing lossMiddle AgedSettore MED/32 - AudiologiaTreatment OutcomeSettore MED/31 - Otorinolaringoiatriamedicine.anatomical_structureHematocrit030220 oncology & carcinogenesisCohortAudiometry Pure-ToneFemalePartial Thromboplastin TimeSteroidsmedicine.symptomPartial thromboplastin timeAdultBlood PlateletsLinguistics and Languagemedicine.medical_specialtyHearing lossHearing Loss Sensorineural03 medical and health sciencesSpeech and HearingAudiogram shapePredictive Value of TestsWhite blood cellmedicineHumansBlood CoagulationRetrospective StudiesProthrombin timePlatelet Countbusiness.industryFibrinogenAuditory ThresholdRetrospective cohort studyRecovery of FunctionHearing Loss Suddenaudiogram shape; haematological parameters; Sudden sensorineural hearing lossProthrombin TimebusinessBiomarkersInternational Journal of Audiology
researchProduct

Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide.

1993

AbstractThe active metabolite of leflunomide, A77 1726 inhibits the proliferation of a variety of mammalian cell lines in culture. Epidermal growth factor (EGF)-dependent proliferation is inhibited by A77 1726 at an effective dose of 30–40 μM. A77 1726 appears to directly inhibit the EGF receptor tyrosine-specific kinase activity both in intact cells and purified EGF receptors at the same effective dose. These data suggest that leflunomide inhibits cellular proliferation by the inhibition of tyrosine-specific kinase activities.

MaleToluidinesmedicine.medical_treatmentBiophysicsHydroxybutyratesBiochemistryKB CellsCell LineHuman foreskin fibroblast cellStructural BiologyEpidermal growth factorNitrilesGeneticsmedicineTumor Cells CulturedAnimalsHumansEpidermal growth factor receptorKinase activityPhosphorylationReceptorMolecular BiologyCells CulturedSkinAniline CompoundsbiologyCell growthKinaseEpidermal growth factor receptorGrowth factorAnti-Inflammatory Agents Non-SteroidalCell BiologyIsoxazolesFibroblastsTyrosine-specific kinaseCell biologyErbB ReceptorsBiochemistryCrotonatesbiology.proteinCarcinoma Squamous CellPlatelet-derived growth factor receptorLeflunomideFEBS letters
researchProduct

Association Between Platelet Endothelial Cellular Adhesion Molecule-1 Polymorphisms and Atherosclerosis: Results of a Study on Patients from Northern…

2010

Adhesion of circulating cells to the arterial surface is among the first detectable events in atherogenesis. Cellular adhesion molecules, expressed by the vascular endothelium and by circulating leukocytes, mediate cell recruitment and their transendothelial migration. Platelet endothelial cellular adhesion molecule-1 (PECAM-1), involved in this migration, has been associated with the development of atherosclerosis. Studies have investigated an association between coronary artery disease (CAD) and single-nucleotide polymorphisms (SNPs) located in functionally important domains of the PECAM-1 gene with inconsistent results. Thus, we have analyzed the distribution of V125L, N563S, and G670R S…

MaleUntranslated regionAgingGenotypeSingle-nucleotide polymorphismCoronary Artery DiseaseBiologyPolymorphism Single NucleotideCoronary artery diseaseGene FrequencymedicineHumansGenetic Predisposition to DiseasePlateletCell adhesionGeneAgedCell adhesion moleculeAdhesionMiddle AgedAtherosclerosismedicine.diseasePlatelet Endothelial Cell Adhesion Molecule-1ItalyCase-Control StudiesImmunologycardiovascular systemFemaleGeriatrics and GerontologyRejuvenation Research
researchProduct